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Background: Anti-resorptive bisphosphonates (BP) are used for the treatment of osteoporosis and bone metastases.
Clinical studies indicated a benefit in survival and tumor relapse in subpopulations of breast cancer patients receiving
zoledronic acid, thus stimulating the debate about its anti-tumor activity. Amino-bisphosphonates in nM concentrations
inhibit farnesyl pyrophosphate synthase leading to accumulation of isopentenyl pyrophosphate (IPP) and the ATP/
pyrophosphate adduct ApppI, which induces apoptosis in osteoclasts. For anti-tumor effects μM concentrations
are needed and a sensitizer for bisphosphonate effects would be beneficial in clinical anti-tumor applications. We
hypothesized that enhancing intracellular pyrophosphate accumulation via inhibition of probenecid-sensitive
channels and transporters would sensitize tumor cells for bisphosphonates anti-tumor efficacy.
Methods: MDA-MB-231, T47D and MCF-7 breast cancer cells were treated with BP (zoledronic acid, risedro-
nate, ibandronate, alendronate) and the pyrophosphate channel inhibitors probenecid and novobiocin. We deter-
mined cell viability and caspase 3/7 activity (apoptosis), accumulation of IPP and ApppI, expression of ANKH, PANX1,
ABCC1, SLC22A11, and the zoledronic acid target gene and tumor-suppressor KLF2.
Results: Treatment of MDA-MB-231 with BP induced caspase 3/7 activity, with zoledronic acid being the most effective.
In MCF-7 and T47D either BP markedly suppressed cell viability with only minor effects on apoptosis. Co-treatment with
probenecid enhanced BP effects on cell viability, IPP/ApppI accumulation as measurable in MCF-7 and T47D cells,
caspase 3/7 activity and target gene expression. Novobiocin co-treatment of MDA-MB-231 yielded identical results
on viability and apoptosis compared to probenecid, rendering SLC22A family members as candidate modulators of BP
effects, whereas no such evidence was found for ANKH, ABCC1 and PANX1.
Conclusions: In summary, we demonstrate effects of various bisphosphonates on caspase 3/7 activity, cell viability
and expression of tumor suppressor genes in breast cancer cells. Blocking probenecid- and novobiocin-sensitive
channels and transporters enhances BP anti-tumor effects and renders SLC22A family members good candidates as BP
modulators. Further studies will have to unravel if treatment with such BP-sensitizers translates into preclinical and
clinical efficacy.
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Bone metastases occur exceptionally often in cancers de-
rived from the breast, the prostate and the kidney. The
biological process of metastasis requires the capability of
extravasation, migration and homing to the bone micro-
environment. Tumor cells when metastasized to bone are
able to activate osteoclasts by secreting osteoclast promot-
ing factors [1]. The latter is the basis of the classical con-
cept of osteolytic metastasis, while the local secretion and/
or activation of latent growth factors contribute to the de-
velopment of osteoblastic metastases and autocrine tumor
propagation [2].
Anti-resorptive bisphosphonates (BP) accumulate in
bone as they show a high affinity to hydroxylapatite and
are incorporated by osteoclasts via phagocytosis [3]. First
generation BP like clodronate induce apoptosis by accu-
mulating toxic ATP adducts whereas second generation
amino-BP inhibit the mevalonate pathway enzyme farne-
syl pyrophosphate synthase (FPPS) very specifically. As a
consequence protein prenylation of small GTP binding
proteins like Rab, Ras or lamins, which are important for
cytoskeleton organization and cellular polarization, is inhib-
ited and may initiate apoptosis [4]. Additionally it was re-
ported for zoledronic acid (ZA) and to a lesser extend for
ibandronate (IBN) and risedronate (RIS) as well as for
alendronate (ALN) that treatment of cells led to the accu-
mulation of isopentenyl pyrophosphate (IPP) and pro-
duced a new endogenous ATP analogue (triphosphoric
acid 1-adenosin-5′-yl ester 3-(3-methylbut-3-enyl) ester
(ApppI)), which also caused apoptosis in osteoclasts by
inhibiting the mitochondrial ADP/ATP translocase [5].
BP have been developed for osteoporosis treatment where
numerous clinical studies proved their efficacy in reducing
the incidence of fragility fractures. When applied in higher
cumulative doses than used for osteoporosis, BP effect-
ively reduced the number of skeletal related events in pa-
tients with bone metastases [6,7], which has made them
an important class of drugs in the treatment of osteolytic
bone diseases [8]. Besides the effects on their classical
targets, cells of the myelomonocytic/macrophage lineage
and especially osteoclasts, BP have been shown to induce
apoptosis in a variety of benign and malignant cells, al-
though in some cases μM concentrations were required [3].
These in vitro effects in concert with clinical studies have
stimulated discussions about a putative clinically relevant
anti-tumor effect of BP. Almost twenty years ago it was
shown that adjuvant treatment with BP reduces the inci-
dence of bone metastases and the overall mortality in pa-
tients suffering from breast cancer. These results were
confirmed in the ABCSG-12 trial, where ZA was used
only twice a year for the adjuvant treatment of estrogen
receptor positive breast cancer patients. Positive long term
effects from patients of the first cohort were reported
in a second analysis more than ten years after thefirst publication [9-11]. Moreover, a synergistic anticancer
efficacy of ZA in combination with neoadjuvant chemo-
therapy was shown in breast cancer patients with re-
spect to additional tumor shrinkage [12]. These effects
were confirmed by the ZO-FAST study, where ZA was as-
sociated with improved disease-free survival in postmeno-
pausal women [13]. However, the discussion is ongoing
and presently a proven anti-tumor effect seems to be re-
stricted to the postmenopausal high bone turnover sub-
population of women suffering from breast cancer [14].
The detailed characterization of the molecular effects
of modern BP like ZA stimulated research about their
effects on both osteoblastic differentiation and on anti-
tumor effects, but a prominent question remained to be
solved, if local μM concentrations of BP can be achieved
in the clinical setting [15,16]. Such high concentrations
are needed because the cellular uptake is relatively poor in
cells other than macrophages and osteoclasts as described
for e.g. free ZA in ovarian tumor cells [17]. However it
was speculated that BP concentrations in the bone micro-
environment and especially in the resorption lacuna can
reach concentrations up to hundreds of μM [18]. The two
most prominent in vitro effects of BP, which may add to
their putative anti-tumor effects, are the capability of in-
ducing apoptosis in tumor cells and eliciting an immune
response. Stimulation of breast cancer cells with bispho-
sphonates and inhibition of the mevalonate pathway as a
consequence leads to the accumulation of IPP and ApppI.
IPP acts as phosphoantigen for γδT cells, which have the
ability to attack the tumor cells [19]. The mechanism by
which IPP is secreted or transported to the outer surface
of a cell is still unknown [20,21]. Channels and trans-
porters for pyrophposphates or ATP might be responsible
for mediating these effects and promising candidates are
pannexin (PANX) hemichannels (especially PANX1), the
progressive ankylosis protein homolog ANKH as well
as organic anion transporters of the solute carrier family
22 (organic anion transporter SLC22A6, SLC22A8 and
SLC22A11) and multidrug resistance associated protein 1
(ABCC1). For PANX1, which is a part of the purinergic
receptor P2RX7 complex, participation in ATP release
was shown [22-24]. ANKH is a transmembrane protein
and controls intra- and extracellular levels of pyrophos-
phate, which is important in bone mineralization [25].
Solute carrier family 22 members are responsible for the
transport of organic anions mainly in the kidney and liver
[26] whereas ABCC1, a member of the human ABC trans-
porter family that is involved in multidrug resistance,
mediates export of organic anions and drugs from the
cytoplasm [27]. All channels and transporters are sensi-
tive to the anion transport blocker probenecid (Prob),
whereas carbenoxolone (CBX) has no effect on ANKH
but is effective in inhibiting PANX1 mediated release.
Ibrutinib was described to block ABCC1 transport while
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fore these substances can be used to distinguish between
ANKH, PANX1, ABCC1 and SLC22A mediated effects.
Sustained effects of bisphosphonates on osteogenic dif-
ferentiation upon treatment with low concentrations and
intermittent treatment with high concentrations of ZA and
alendronate were previously demonstrated [32,33], while
permanent exposure to high doses induced apoptosis in
both tumor cells and osteogenic precursors [32,34,35]. In
MCF-7 cells we identified ZA target genes as KLF2, KLF6
and Ki-67 and we assumed that IPP/ApppI accumula-
tion might mediate this effect in cell populations that
are largely insensitive to apoptosis induction [15]. It is ofM
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Figure 1 Cell viability and caspase 3/7 activity in breast cancer ce
caspase 3/7 activity (D-F) in MCF-7, T47D and MDA-MB-231 breast can
ibandronate (IBN, open triangles), alendronate (ALN, filled squares) and
of six different measure points of three independent experiments as p
Mann–Whitney U test (**p < 0.001, *p < 0.01, #p < 0.05).major importance to unravel the differential potency of
various BP on tumor cell growth and apoptosis and to de-
scribe the downstream targets in non-osteoclastic cells.
Here we show that breast cancer cell lines permanently
exposed to various BP (zoledronic acid, ibandronate, alen-
dronate, risedronate) undergo apoptosis (MDA-MB-231,
to a lesser extend T47D) or show reduced viability (MCF-7).
The relative potency of various BP mirrors their antiosteo-
lytic potency with ZA inducing the greatest increase in
apoptosis. Interestingly, all other BP tested were almost
equally potent in reducing MCF-7 viability. Co-incubation
with the anion transporter and channel blocking agent
probenecid and novobiocin revealed a synergistic effect,F
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Figure 2 Detection of IPP and ApppI in breast cancer cells
treated with various bisphosphonates. IPP (A) and ApppI (B) were
measured in bisphosphonate-stimulated MCF-7 and T47D breast
cancer cells. All data are expressed as means of three independent
experiments ± SEM (ZA: zoledronic acid, RIS: risedronate, IBN:
ibandronate, ALN: alendronate, n.d.: not detectable).
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be secreted to the extracellular space and according to
previously described sensitivity renders SLC22A family
members as good candidates for the sensitizing effects.
Bisphosphonates have relevant effects on tumor cell biol-
ogy and an adjuvant therapy with BP in combination with
a respective sensitizer might be useful in the treatment of
breast cancer.
Results
Permanent incubation of breast cancer cell lines with
different bisphosphonates modulates cell viability and
caspase 3/7 activity
MCF-7, T47D and MDA-MB-231 cells were subjected to
various concentrations of ZA, IBN, ALN and RIS (5, 20,
50 and 100 μM) for 72 h (Figure 1). In MCF-7 cell viability
was inhibited by all used bisphosphonates (Figure 1A).
100 μM ZA and ALN suppressed the viability to 40%, RIS
and IBN to 50 – 60%. In T47D cells ZA inhibited the
viability to 40% starting from 20 μM with no increasing
effects when higher doses were used. ALN was less potent
when applied at 20 and 50 μM but showed the same in-
hibition at 100 μM. RIS and IBN reduced cell viability only
to approx. 70 and 80% in a U-shaped manner when ap-
plied in doses of 50 μM and higher (Figure 1B). ZA was
most potent in inhibiting the viability of MDA-MB-231
cells (Figure 1C, filled triangles). 20 and 50 μM ZA re-
duced cell viability to 50 and 20%, respectively. IBN (open
triangles) and ALN (filled squares) were less potent, while
RIS (open squares) had almost no effect.
In MCF-7 cells only ZA showed marginal effects on cas-
pase 3/7 induction (Figure 1D) while in T47D cells only
ZA and ALN slightly enhanced caspase 3/7 activity when
applied in 50 and 100 μM doses (Figure 1E). When analyz-
ing caspase 3/7 activity of MDA-MB-231 cells (Figure 1F)
treated with different bisphosphonates 100 μM ZA in-
duced a 5-fold enhancement (filled triangles), while IBN
(open triangles) was able to increase caspase 3/7 activity
2-fold compared to ALN (filled squares, 1.5-fold) at the
same concentration. RIS (open squares) had no effect on
caspase 3/7 activity in MDA-MB-231 cells. No effect of
ZA on cytotoxicity could be observed (data not shown).
Significances were calculated with the Mann–Whitney
U test by comparison of the untreated controls to the
stimulated values (**p < 0.001, *p < 0.01, #p < 0.05).
Bisphosphonate treatment induces IPP/ApppI production
in breast cancer cells
The accumulation of IPP and ApppI was analyzed in
MCF-7, T47D and MDA-MB-231 breast cancer cells
after treatment with the bisphosphonates ZA, RIS, IBN
and ALN, respectively. By comparing the three different
cell lines high concentrations of IPP were detected in
T47D and MCF-7 cells while ApppI concentrations werehigh in T47D and moderate in MCF-7 cells. No reprodu-
cible amounts of IPP and ApppI could be measured in
MDA-MB-231 cells as it was reported before [19] (data
not shown). In T47D cells ZA induced high amounts of
IPP (6,820 pmol/mg protein) while RIS treatment resulted
in the accumulation of moderate levels (5,500 pmol/mg
protein) (Figure 2A, right bars) in contrast to ALN and
IBN, which induced lower IPP accumulation (3,336 pmol/
mg protein and 2,838 pmol/mg protein, respectively) al-
though with high variability when IBN was applied. Deter-
mination of ApppI revealed similar concentrations after
treatment with ZA and RIS (1,210 and 1,165 pmol/mg
protein) (Figure 2B, right bars). Determination of ApppI
concentrations after ALN treatment showed a moderate
induction of 742 pmol/mg protein while IBN treated cells
accumulated only 294 pmol ApppI/mg protein. In MCF-7
cells ZA and RIS stimulation resulted in the accumulation
of 4,674 and 4,520 pmol IPP/mg protein while values for
ALN treated cells were moderate (3,250 pmol/mg protein)
with IPP only detectable in two out of three ALN treated
samples. IPP concentrations for IBN treated cells were
lowest (940 pmol/mg protein) (Figure 2A, left bars). ApppI
values in MCF-7 cells were much lower compared to the
Ebert et al. Molecular Cancer 2014, 13:265 Page 5 of 13
http://www.molecular-cancer.com/content/13/1/265values observed in T47D cells. In ZA, RIS and ALN stimu-
lated cells ApppI values were between 191 and 156 pmol/
mg protein, with ApppI only detectable in two out of three
ALN treated samples. ApppI was only measureable in one
out of three samples in IBN treated cells (Figure 2B, left
bars). In MDA-MB-231 cells IPP and ApppI were detect-
able in only one out of three samples (data not shown).
Probenecid co-treatment enhances bisphosphonate
effects on cell viability and caspase 3/7 activity
MCF-7, T47D and MDA-MB-231 breast cancer cells
were stimulated with 20, 50 and 100 μM ZA, RIS, IBN,
or ALN, respectively (Figure 3, black lines) and co-
treated with 0.25 mM probenecid (Prob, Figure 3, dotted
lines) for 72 h. Determination of cell viability in MCF-7
cells (Figure 3A-D) revealed a synergistic effect of pro-
benecid on BP effects compared to BP alone with almost
parallel curves in terms of RIS and IBN. In ZA and ALN
treated cells, probenecid showed additive effects when
submaximal BP doses of 20 μM were applied. With a
higher BP dosing the curves almost converged. In T47D
cells (Figure 3E-H) Prob and RIS co-stimulation had no
additive effect on the inhibition of cell viability com-
pared to cells treated with RIS alone in contrast to ZA
or IBN stimulated cells, where Prob co-treatments in-
creased the inhibitory effect of the respective BP. The ef-
fects of ZA and IBN obtained in T47D and MCF-7 cells
were comparable in contrast to ALN stimulated T47D
cells where the pattern of cell viability was different to
all other BP. Prob co-stimulation had maximal effects at
an ALN range between 20 and 50 μM and depicted much
less impact on cell viability at higher BP concentrations.
In MDA-MB-231 cells (Figure 3I-L) ZA/Prob and ALN/
Prob co-treatment experiments revealed comparable re-
sults as well as in RIS/Prob and IBN/Prob treated speci-
mens, respectively. The graphs of RIS and IBN single
treated cells diverged from the RIS/Prob and IBN/Prob
co-stimulations with a maximum at 100 μM BP, whereas
the graphs of ZA and ALN single treated cells diverged
from the ZA/Prob and ALN/Prob co-treatments max-
imally at a concentration of 20 μM BP and converged at
higher doses at 100 μM.
Determination of caspase 3/7 activity in BP/Prob co-
stimulated MCF-7 cells (Figure 3M-P) revealed an activ-
ity induction at concentrations of 20 and 50 μM ZA and
RIS after Prob stimulation, whereas the combination of
20 μM IBN and Prob inhibited caspase 3/7 activity in
contrast to doses of 50 and 100 μM IBN where Prob
had a slight but measurable additive effect. No additive
effect of Prob and ALN could be observed. In T47D cells
(Figure 3Q-T) no caspase 3/7 activity was induced by
RIS and IBN, as we have already shown in Figure 1, and
IBN/Prob or RIS/Prob co-stimulations did not show any
activity induction, RIS/Prob even reduced the measuredcaspase 3/7 activity. An additive effect of ZA/Prob was
seen compared to ZA single stimulated samples at 50
and 100 μM ZA whereas the combination of ALN and
Prob showed massive effects on caspase 3/7 activity induc-
tion at all ALN concentrations compared to ALN stimula-
tions alone. When we determined the activity of caspase
3/7 in MDA-MB-231 (Figure 3U-X) after stimulating cells
with BP alone or in combination with Prob we observed
an additive effect of Prob/BP in combination compared to
BP alone in ZA and ALN treated cells at 20 and 50 μM
BP, although at higher doses of 100 μM caspase 3/7 activ-
ity was diminished in the BP/Prob samples compared to
the BP stimulated specimens. IBN/Prob co-treatment in-
creased caspase 3/7 activity compared to IBN single stim-
ulated cells at all concentrations whereas in RIS treated
cells RIS/Prob co-treatment had the opposite effect and
caspase 3/7 activity was reduced.
Significances were calculated with the Mann–Whitney
U test by comparison of the BP stimulated samples to
the BP/Prob co-treated values (**p < 0.005, *p < 0.05).
Probenecid enhances BP-induced IPP/ApppI accumulation
IPP and ApppI accumulation was measured in breast can-
cer cells after co-stimulation with bisphosphonates and
probenecid. In MCF-7 cells (Figure 4A) Prob co-treatment
significantly increased the BP induced accumulation of
IPP (black bars) in ZA, RIS and IBN treated samples. The
highest effect was obtained after IBN/Prob co-stimulation,
where a 3.2-fold increase of IPP values was obtained com-
pared to IBN treatment alone. The determination of ApppI
revealed only a significant additive effect of Prob on ZA
treated samples (grey bars). In only two out of three ALN/
Prob co-stimulated samples IPP and ApppI could be de-
tected while only one out of three IBN/Prob samples
depicted ApppI accumulation. In T47D cells (Figure 4B)
Prob co-treatment increased the BP induced accumulation
of IPP (black bars) and ApppI (grey bars) with significant
values in RIS and ALN specimens in terms of IPP and
significant values in ZA, RIS and ALN treated samples
in terms of ApppI accumulation. The combination Prob/
ALN was most effective with a 3-fold increase in IPP and
a 3.5-fold increase in ApppI accumulation compared
to ALN treated samples alone. In MDA-MB-231 cells
IPP could be detected after ZA/Prob and ALN/Prob
co-treatment. All other samples were negative for IPP
and ApppI, respectively (data not shown). Significances
were calculated from the means of three independent
experiments with the Mann–Whitney U test (**p < 0.005,
*p < 0.05).
Probenecid co-treatment enhances bisphosphonate-induced
expression of the target gene KLF2
We have previously identified KLF2 as a target gene of ZA
in MCF-7 cells [15] and postulated its specific upregulation
Figure 3 (See legend on next page.)
Ebert et al. Molecular Cancer 2014, 13:265 Page 6 of 13
http://www.molecular-cancer.com/content/13/1/265
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Figure 3 Cell viability and caspase 3/7 activity in breast cancer cells co-treated with probenecid and bisphosphonates. Cell viability
(A-L) and caspase 3/7 activity (M-X) was determined in MCF-7, T47D and MDA-MB-231 breast cancer cells after treatment with ZA (zoledronic
acid), RIS (risedronate), IBN (ibandronate), ALN (alendronate) alone and in combination with probenecid. All data are expressed as means of six
different measure points of three independent experiments as percent of controls ± SEM. Significances were calculated with the Mann Whitney
U test (**p < 0.005, *p < 0.05). BP: bisphosphonate, black line; Prob: probenecid, dotted line probenecid co-treatment.
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and inhibition of protein prenylation. We analyzed if other
BP are also able to modulate KLF2 expression in breast
cancer cells and if probenecid can enhance the observed
effects. In MCF-7 cells ZA induced a 13-fold increase in
KLF2 expression, which was further enhanced by Prob co-
treatment (32.4-fold expression) compared to untreated
controls (Table 1). Additive effects of Prob were also ob-
served when using ALN. The bisphosphonate alone in-
duced KLF2 expression by the factor 5.8 with a further
stimulatory effect of Prob co-treatment to a 36.1-fold in-
duction. IBN alone had no impact on KLF2 expression but0
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Figure 4 Induction of IPP and ApppI in bisphosphonate-stimulated
breast cancer cells by probenecid. MCF-7 (A) and T47D (B) cells were
treated with ZA (zoledronic acid), RIS (risedronate), IBN (ibandronate),
ALN (alendronate) alone and in combination with probenecid
(Prob). All data are expressed as means of three independent
experiments ± SEM. The induction of IPP (black bars) and ApppI
(grey bars) in BP stimulated cells by Prob is shown. Significances were
calculated with the Mann–Whitney U test (**p < 0.005, *p < 0.05).with Prob co-stimulation the expression of KLF2 increased
6.1-fold in contrast to RIS, where no co-stimulatory effect
of Prob on the absent RIS effect could be observed.
In MDA-MB-231 cells ZA and IBN had no significant
impact on KLF2 expression but Prob was able to increase
KLF2 expression 5.1-fold in ZA and 4.8-fold in IBN co-
stimulatory experiments. RIS alone increased KLF2 expres-
sion by the factor 3.5 but Prob co-treatment abandoned
the effect to a non-significant expression. No effect was
seen when ALN was used, independent of Prob co-
treatment.
In T47D cells no additive effect of Prob was detectable.
ZA increased KLF2 expression 3.0 fold but Prob had no
additive effect (2.6-fold expression) just as in terms of IBN,
where both IBN and IBN/Prob treated samples showed an
upregulation of KLF2 by the factor 2.2. RIS alone increased
KLF2 expression by the factor 2.1 but no significant en-
hancement was detectable in RIS/Prob treated cells. ALN
alone or the combination ALN/Prob did not influence the
expression of KLF2.
Breast cancer cells express probenecid sensitive channels
and transporters
The expression of the pyrophosphate channel ankylosis
protein homolog (ANKH), the hemichannel protein pan-
nexin 1 (PANX1), multidrug resistance associated protein
1 (ABCC1) and solute carrier family 22 (organic anionTable 1 Effects of co-treatment of breast cancer cell lines
with probenecid and bisphosphonates on the expression
of KLF2
KLF2 expression MCF-7 T47D MDA-MB-231
ZA 20 μM 13.0** (2.3-60.8) 3.0* (1.2-7.6) 3.1 (0.6-16.0)
ZA + Prob 32.4** (5.8-198.5) 2.6* (1.0-6.7) 5.1* (0.7-25.6)
RIS 50 μM 1.6 (0.3-10.1) 2.1* (1.0-3.7) 3.5* (0.6-18.8)
RIS + Prob 4.2 (0.7-35.9) 1.7 (0.7-4.7) 3.4 (0.5-19.2)
IBN 50 μM 2.4 (0.5-15.2) 2.2* (0.9-4.9) 2.4 (0.3-17.3)
IBN + Prob 6.1* (0.8-31.7) 2.2* (0.9-5.9) 4.8** (0.7-28.4)
ALN 50 μM 5.8* (1.2-33.4) 2.0 (0.8-5.5) 1.4 (0.2-11.4)
ALN + Prob 36.1** (9.7-141.4) 1.8 (0.8-5.6) 3.2 (0.4-31.1)
Prob 1.0 (0.3-5.0) 1.0 (0.8-1.3) 1.3 (0.1-9.4)
The expression ratios of KLF2, in MCF-7, T47D and MDA-MB-231 breast cancer
cells after treatment with ZA (zoledronic acid), RIS (risedronate), IBN (ibandronate),
ALN (alendronate) alone and in combination with probenecid (Prob) compared
to untreated controls and normalized to 36B4 (acidic ribosomal phosphoprotein
P0) are shown. (**p < 0.001, *p < 0.01 calculated with REST [38]).
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SLC22A11) were analyzed in breast cancer cells. PANX1
transcripts could be detected in high amounts in all tested
cell lines. ANKH was highly expressed in MCF-7 and
MDA-MB-231 cells in contrast to T47D cells where only
a faint PCR band was visible. ABCC1 was highly expressed
in MCF-7 cells and lower in T47D and MDA-MB-231
cells. SLC22A11 was expressed in T47D and MDA-MB-
231 but not in MCF-7 cells (Figure 5). SLC22A6 and
SLC22A8 mRNAs were not detectable in all analyzed
breast cancer cell lines. QPCR quantification of ANKH
expression revealed a 0.18-fold (p < 0.05) lower expression
in MCF-7 cells and a 0.07-fold (p < 0.001) lower expres-
sion in T47D cells compared to MDA-MB-231 cells
whereas PANX1 and ABCC1 expression varied between
the cell lines but without any significance. Values were
normalized to 36B4 expression (MDA-MB-231 vs. MCF-7)
and GAPDH (MDA-MB-231 vs. T47D). Immunocyto-
chemical staining of ANKH and PANX protein con-
firmed these results with MCF-7 and MDA-MB-231
cells expressing high levels, and T47D expressing low
levels of ANKH while PANX1 was equally expressed
among the cell lines (Additional file 1: Figure S1).ANKH
EF1α
PANX1
ABCC1
SLC22A11
Figure 5 Expression of probenecid-sensitive channels and
transporters in breast cancer cells. RT-PCR detection of ANKH
(progressive ankylosis protein homolog), PANX1 (pannexin 1),
multidrug resistance associated protein 1 (ABCC1) and SLC22A11
(solute carrier family 22 member 11) in MCF-7, T47D and MDA-MB-231
cells. EF1α (eukaryotic elongation factor 1 α) was amplified as a
housekeeping gene (n.c.: negative control).ANKH overexpression does not alter probenecid response
of BP effects on cell viability
Expression of ANKH in stably transfected T47D cells
(T47D-pCMV-ANKH) was confirmed by RT-PCR on
mRNA (Additional file 2: Figure S2A) and by immuno-
cytochemistry on protein level (Additional file 2: Figure S2B).
When ANKH overexpressing T47D cells and T47D
control cells carrying the empty pCMV vector were stim-
ulated with 20 and 50 μM ZA (Additional file 2: Figure
S2C, black line) and co-stimulated with 0.25 mM Prob
(Additional file 2: Figure S2C, dotted line) no difference
between the two cell lines was observed in terms of cell
viability and caspase 3/7 activity.
Novobiocin but not carbenoxolone or ibrutinib
co-treatment modulates bisphosphonate effects on cell
viability and caspase 3/7 activity in MDA-MB-231 breast
cancer cells
To further identify the putative channel or transporter re-
sponsible for the observed synergistic effects of Prob on
BP treatment we applied additional blockers for pyrophos-
phate channels, organic anion transporters and blockers
for multidrug resistance associated protein 1. MDA-MB-
231 breast cancer cells were stimulated with 50 μM ZA,
RIS, IBN, or ALN, respectively and co-treated with 50 μM
carbenoxolone (CBX), a blocker of PANX1, 100 μM novo-
biocin, a blocker for solute carrier family 22 member 6, 8
and 11 (SLC22A6, SLC22A8, SLC22A11) and 50 μM ibru-
tinib, an inhibitor for multidrug resistance associated
protein 1 (ABCC1) for 72 h. Determination of cell viabil-
ity showed a synergistic effect on the inhibition of cell
viability of CBX and ZA compared to ZA alone in MDA-
MB-231 cells, all other combinations had no significant ef-
fects (Figure 6A). No synergistic effect of CBX in terms of
caspase 3/7 activity induction compared to bisphospho-
nate stimulations alone could be observed (Figure 6B).
Novobiocin plus BP synergistically and highly signifi-
cantly reduced cell viability of MDA-MB-231 cells with
novobiocin/ZA being the most potent combination com-
pared to BP stimulations alone (Figure 6A). Caspase 3/7
activity was synergistically and significantly induced by
the combination novobiocin/RIS and novobiocin/IBN
while novobiocin/ZA decreased caspase 3/7 activity com-
pared to BP treatment alone (Figure 6B). Ibrutinib plus
ZA significantly induced cell viability compared to BP
treatment alone (Figure 6A) while caspase 3/7 activity was
significantly decreased by the combination ibrutinib/ZA
and ibrutinib/ALN compared to BP alone (Figure 6B).
Carbenoxolone, novobiocin and ibrutinib alone did not
influence cell viability and caspase 3/7 activity (data not
shown). Significances were calculated with the Mann–
Whitney U test by comparison of the BP stimulated
samples to the BP/CBX co-treated values (*p < 0.05;
**p < 0.005).
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Figure 6 Cell viability and caspase 3/7 activity in MDA-MB-231 cells co-treated with carbenoxolone, novobiocin, ibrutinib and
bisphosphonates. Cell viability (A) and caspase 3/7 activity (B) was determined after treatment with ZA (zoledronic acid), RIS (risedronate), IBN
(ibandronate), ALN (alendronate) in combination with carbenoxolone, novobiocin and ibrutinib. All data are expressed as means of three different
measure points of three independent experiments ± SEM and were normalized to BP treatment alone. Significances were calculated with the
Mann Whitney U test (*p < 0.05; **p < 0.005).
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Apart from osteoclasts, BP may have clinically relevant
effects on benign and malignant cells. We found variable
efficacies of different BP on cell viability and caspase 3/7
activity of the breast cancer cell lines MDA-MB-231,
T47D and MCF-7. The most potent BP in MDA-MB-231
cells with respect to caspase 3/7 activity induction was
ZA, while other BP were markedly less effective in the de-
scending order IBN >ALN > RIS when applied in equimo-
lar concentrations. In the apoptosis insensitive cell lines
the picture was different with ZA showing high efficacy
on the reduction of cell viability in T47D cells followed by
ALN, IBN and RIS in contrast to MCF-7 cells where ZA
and ALN depicted comparable effects followed by the
weaker compounds RIS and IBN. The observed differ-
ences cannot be explained by the rank order of BP in their
potency to inhibit the target enzyme farnesyl pyrophos-
phate synthase (FPPS) with ZA and RIS depicting the
highest potency followed by the much weaker inhibitors
IBN and ALN [4]. Differences in cellular BP uptake and
retention might be responsible for these observations.
Nothing is known if all BP are incorporated with the same
efficacy, also the mechanism by which tumor cells take upBP is under discussion. The process of pinocytosis might
be relevant but the transport through a channel protein
cannot be excluded. At pH 7.4 the amino-BP differ in their
zeta potential as the R2 groups of ZA, ALN and IBN are
positively charged in contrast to RIS, where the group is
negatively charged [4]. Analyses with nanoparticles re-
vealed that positively charged particles are more likely
engulfed by pinocytosis than negatively charged particles
[36] but also a channel protein or a transporter might dis-
tinguish between the different groups in favor of the posi-
tively charged BP. Both processes would lead to reduced
RIS uptake possibly explaining the weak effects of this
compound in tumor cells.
The determination of IPP accumulation and ApppI for-
mation revealed differences between the analyzed breast
cancer cell lines and the various BP. In T47D cells we de-
tected high levels of IPP/ApppI and in MCF-7 cells high
to moderate levels of IPP and low levels of ApppI as re-
ported previously [19]. In MDA-MB-231 cells IPP and
ApppI were only measurable in single samples. ZA was
the most potent BP in inducing IPP/ApppI followed by
RIS and ALN and IBN being the weakest compound. Our
data are not in line with observations in J774 macrophages
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by RIS, IBN and ALN [5], which is similar to their known
order of affinity to FPPS and we again speculate that
cells incapable of phagocytosis reflect mechanisms for
BP uptake, which distinguish between differently charged
BP.
Tumor cells are capable of releasing IPP to the extracellu-
lar space, which can bind to an unknown antigen-presenting
molecule to be recognized by the T-cell receptor of γδT-cells
[20,21]. The mechanisms by which IPP is secreted are un-
known and we assumed that the pyrophosphate channels
PANX1 and/or ANKH or organic anion transporters as
ABCC1 and/or members of the organic anion transporter
family SLC22A might mediate this release. All analyzed
breast cancer cells depicted similar expression levels of
PANX1 and ABCC1 whereas a considerable variability of
ANKH and SLC22A11 expression was observed. At first
our lead candidate was ANKH but by establishing ANKH
transgenic T47D cells we were able to exclude its rele-
vance. We further hypothesized that blocking the above
mentioned channels and transporters and subsequently
inhibiting the release of BP-induced pyrophosphates en-
hances IPP/ApppI accumulation, leading to an increase in
the BP effect on tumor cell viability. Co-stimulation with
the PANX1 inhibitor CBX or the ABCC1 inhibitor ibruti-
nib together with BP did not result in an appreciable syn-
ergistic effect in contrast to a co-stimulation with BP and
the organic anion transporter and pyrophosphate channel
blocking agent probenecid (Prob) or the SLC22A blocker
novobiocin. Both probenecid and novobiocin revealed
remarkable additive effects on BP-mediated cell viability
reduction and caspase 3/7 activity induction in certain
conditions. Therefore we hypothesize that solute carrier
family 22 (organic anion transporter) members might be
the main candidates to release IPP into the extracellular
space. By blocking SLC22A members the described effects
of BPs on tumor cells can be intensified.
Furthermore we tried to find out if the additive effect
of Prob and BP on tumor cell viability is consistent with
an increase in intracellular IPP and ApppI. The most re-
markable induction of pyrophosphate accumulation was
observed in samples showing low BP-induced IPP/ApppI
levels like in IBN and ALN treated T47D cells. T47D
cells are generally able to accumulate IPP/ApppI in high
amounts as it was reported before [19]. MCF-7 lack the ex-
pression of SLC22A11 while T47D show only low expres-
sion of ANKH in contrast to MDA-MB-231 cells. MDA
cells produce comparably high levels of the three chan-
nels/transporters ANKH, PANX1 and SLC22A11 and this
is a possible explanation why the intracellular levels of IPP
and consecutively ApppI can not be measured.
Equimolar concentrations of IPP and AMP are neces-
sary for the formation of ApppI, catalyzed by aminoacyl-
tRNA synthase enzymes. The concentration of AMP isdependent on the cellular energy metabolism. ApppI for-
mation sequestrates AMP, which is then not available for
mitochondrial ATP regeneration and ApppI itself blocks
the adenine nucleotide translocases, which catalyzes the
exchange of cytoplasmic ADP with mitochondrial ATP
across the mitochondrial inner membrane. The molecu-
lar consequences of ATP deficiency are a negative energy
balance and either reduction of proliferation or apop-
tosis induction, the latter being dependent on the indi-
vidual susceptibility of cells to induce the apoptosis
program. This condition is perfectly reflected by the
ATP-based proliferation measurement, which we used
for the determination of cell viability. The intracellular
pool of nucleotides for energy metabolism and nucleic
acid synthesis appears to be different in the used cell
lines. In apoptosis sensitive cells this leads to caspase 3/
7 activity induction while in resistant cells proliferation
is inhibited.
Our data may also shed light on the mechanisms of
regulation of intracellular versus extracellular concentra-
tions of phosphate compounds through channel-mediated
release in general. As we showed earlier, ZA enhanced
mineralization of osteogenic precursors in vitro [32]. Inor-
ganic pyrophosphates are inhibitors of mineralization and
upon inhibition of the delivery of these pyrophosphates
to the cell surface through both stimulation of intra-
cellular decoy mechanisms and inhibition of channel
delivery mineralization should be increased around cells
that are able to perform coordinated mineralization pro-
cesses. Further research will have to unravel this pu-
tatively pathology-relevant role of channel activity.Conclusion
In summary, we report an antitumor activity of all amino-
BP, which can be enhanced through inhibition of a putative
channel for IPP and by the consecutive rise of intracellular
substrates and products of ATP-derived adducts. Probene-
cid, approved as an uricosuric compound, which inhibits
the reabsorption of uric acid, and the antibiotic novobi-
ocin, are accredited compounds. If the effect of enhancing
anti-tumor effects of BP using concomitant probenecid or
novobiocin treatment can be translated into preclinical
and clinical settings without deleterious off-target effects
remains to be proven.Methods
Cell culture
All media were obtained from Life Technologies GmbH
(Darmstadt, Germany), fetal calf serum (FCS) was obtained
from Biochrom AG (Berlin, Germany). MCF-7, MDA-MB-
231 and T47D cells were cultivated as described previously
[15]. As all experiments were performed with cell lines an
ethical approval was not required.
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2.5 × 105 T47D cells per well were seeded on 6well
plates and transfected with 2.5 μg pCMV-ANKH (Sino
Biological Inc., Beijing, PR China) or the empty pCMV
vector, both linearized with SspI (New England Biolabs,
Frankfurt, Germany), by using LipofectAMINE 2000 (Life
Technologies GmbH, Darmstadt, Germany) according to
the manufacturer’s instructions. As selection antibiotics
100 μg/ml hygromycin (Life Technologies GmbH) was
added with every medium change.
Determination of cell viability and caspase 3/7 activity
For determination of effects of bisphosphonates on cell
viability and caspase 3/7 activity MDA-MB-231, T47D and
MCF-7 as well as T47D-pCMV-ANKH and T47D-pCMV
control cells were seeded on 96-well plates with a density
of 1000 cells/well and were stimulated with 5, 20, 50 and
100 μM zoledronic acid (ZA), ibandronate (IBN), alendro-
nate (ALN) and risedronate (RIS) (AXXORA GmbH,
Lörrach, Germany) for 72 h. To analyze effects of pro-
benecid (Prob) co-treatment MCF-7, MDA-MB-231 and
T47D cells were stimulated with 0.25 mM Prob (Sigma
Aldrich GmbH) together with 20, 50 or 100 μM ZA, ALN,
RIS and IBN, respectively. Additional co-stimulatory ex-
periments were performed by using 50 μM carbenoxolone
(CBX, Sigma Aldrich GmbH), 5 μM ibrutinib, 100 μM
novobiocin (both Selleckchem, Houston, USA) together
with 50 μM of each bisphosphonate. Cell viability and
caspase 3/7 activity were determined after 72 h with
the CellTiter-Glo Luminescent Cell Viability Assay and the
Caspase-Glo 3/7 Assay (both Promega GmbH, Mannheim,
Germany) according to the manufacturer’s instructions
as described previously [15]. Cytotoxicity was determined
in MCF-7 and MDA-MB-231 cells after ZA treatment by
using the CytoTox-Fluor™ Cytotoxicity Assay (Promega
GmbH) according to the manufacturer’s instructions.
Significances were calculated with the Mann–Whitney U
Test by comparison of the untreated control to the stimu-
lated values and by comparison of BP treated cells to BP/
Prob or BP/CBX co-stimulated cells.
RT-PCR
Total RNA was isolated from MCF-7, T47D and MDA-
MB-231 cells by using the NucleoSpin RNA II kit
(Macherey-Nagel, Düren, Germany) according to the
manufacturer’s instructions. Two micrograms of total
RNA were reverse-transcribed with MMLV reverse tran-
scriptase (Promega GmbH) in a volume of 25 μl. For
amplification of ABCC1, ANKH, PANX1, SLC22A6,
SLC22A8, SLC22A11 and the housekeeping gene EF1α
1 μl of cDNA was used as a template in a volume of
50 μl. Taq DNA polymerase was obtained from Promega
GmbH and primers were obtained from biomers GmbH,
Ulm, Germany with the following sequences in 5′-3′direction: ABCC1for GGATTTTTGCTGTGGATCGT; AB
CC1rev ACCAGCCAGAAAGTGAGCAT; ANKHfor AAA
GCCGTCCTGTGTATGGT; ANKHrev CAGGGATGATG
TCGTGAATG; PANX1for AGAGCGAGTCTGGAAACC;
PANX1rev CAAGTCTGAGCAAATATGAGG; SLC22A6for
GTCTGCAGAAGGAGCTGACC; SLC22A6rev GTCCAC
AGCACCAAAGATCA; SLC22A8for CTGAGCACCGTC
ATCTTGAA; SLC22A8rev TGGTGTCCACCAGGATGA
TA; SLC22A11for CTGCCCTCTTGCTCAGTTTC; SLC
22A11rev CACTGGCGTTGGAAAGAGTT; EF1αfor AGG
TGATTATCCTGAACCATCC; EF1αrev AAAGGTGGAT
AGTCTGAGAAGC. PCR conditions were as follows: 30 s,
94°C; 30 s, annealing temperature (54°C EF1α, 55°C ANKH,
57°C PANX1, 60°C ABCC1, SLC22A6 and SLC22A11,
62°C SLC22A8), 30 s, 72°C; 35 cycles. PCR bands were
analyzed by agarose gel electrophoresis.
Quantitative PCR
MDA-MB-231, T47D and MCF-7 cells were treated for
72 h with 20 or 50 μM ZA, RIS, IBA, ALN as indicated and
co-treated with 0.25 mM probenecid. Quantitative PCR
(qPCR) was performed in 20 μl by using 1 μl of the cDNA,
which was previously diluted 1:5 and 10 μl of KAPA SYBR
FAST qPCR Universal Mix (Peqlab Biotechnologie GmbH,
Erlangen, Germany) and 2.5 μl of primer pairs for human
KLF2 or GAPDH as housekeeping gene (Quantitect Hs_
KLF2_1 and Hs_GAPDH_1_SG, Qiagen GmbH, Hilden,
Germany), dissolved according to the manufacturer’s
instructions. The primers for 36B4, which was used as
housekeeping gene, and the primers for ABCC1, ANKH,
and PANX1 (see above) were obtained from biomers.net
GmbH, Ulm, Germany and were used in a concentration
of 1 pmol each per reaction with the following sequences
in 5′-3′ direction: 36B4_qFor: TGCATCAGTACCCC
ATTCTATCAT; 36B4_qRev: AGGCAGATGGATCAG
CCAAGA [37]. QPCR conditions were as follows: 95°C,
3 min; 40 cycles: 95°C, 15 s; 60°C, 15 s; 72°C, 20 s;
followed by melting curve analysis for specificity of qPCR
products. QPCR was performed with the Opticon DNA
Engine (MJ Research, Waltham, USA). Data were obtained
from three independent experiments and qPCRs were
performed three times. Results were calculated with the
Relative Expression Software Tool (REST 2009 V2.0.13)
obtained from Qiagen GmbH [38].
Immunocytochemistry for ANKH and PANX1
Breast cancer cells were seeded on coverslips in 6well
plates, grown over night, washed thrice with PBS, fixed for
5 min with ice-cold methanol, dried and stored at −80°C
until staining. Before staining cells were washed with PBS,
permeabilized with PBS/0.05% Tween-20, washed again
with PBS, and blocked with 3% BSA in PBS. Cells were
incubated with the primary antibodies for ANKH (1:300
(sc-67242) and PANX1 (1:500 sc-49695), respectively
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for 16 h at 4°C and a phycoerythrin-labeled secondary
antibody (NorthernLights anti-mouse IgG-NL557, RnD
Systems, NL007, 1:400) for 2 h at RT. The coverslips were
transferred on slides with a drop of Vectashield with DAPI
(LINARIS GmbH, Wertheim, Germany) and analyzed
under a fluorescence microscope (Axioskop2, filters 1 and
20, Carl Zeiss MicroImaging GmbH, Jena, Germany).
Determination of IPP and ApppI in cell samples
IPP and ApppI were determined as described previously
[5]. Briefly, 1 × 106 MCF-7, MDA-MB-231 and T47D cells/
well were seeded on 6well plates and incubated overnight.
MCF-7 cells were stimulated with 20 μM ZA and 50 μM
of all other BP (RIS, IBN, ALN), MDA-MB-231 and T47D
cells were treated with 50 μM BP (ZA, RIS, IBN, ALN),
0.25 mM Prob or the combination of each BP and Prob
for 24 h, washed with ice-cold PBS and harvested. IPP/
ApppI was extracted with ice-cold acetonitrile (300 μl)
and water (200 μl) containing 0.25 mM NaF and Na3VO4
as phosphatase inhibitors. IPP and ApppI were quantified
with HPLC-ESI-MS, protein contents were determined
by the BCA method (Perbio Science Deutschland, Bonn,
Germany). Values were obtained from three independent
experiments.
Additional files
Additional file 1: Figure S1. Immunocytochemical staining of ANKH
and PANX1, nuclei are stained with DAPI. Representative images are
shown, the bar represents 100 μm.
Additional file 2: Figure S2. Overexpression of ANKH in T47D cells. A)
Amplification of ANKH in pCMV-ANKH and pCMV stable cell lines. EF1α
was used as a housekeeping gene. B) Immunocytochemical staining of
ANKH in pCMV-ANKH and pCMV stable T47D cells. Nuclei are stained
with DAPI. Representative images are shown, the bar represents 100 μm.
C) Cell viability and caspase 3/7 activity in pCMV-ANKH and pCMV stable
T47D cells co-treated with probenecid and ZA. All data are expressed as
means of six different measure points of three independent experiments
as percent of controls ± SEM. BP: bisphosphonate, black line; Prob: probenecid,
dotted line probenecid co-treatment.
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